申報人需遵守以下所有規定☒

由非註冊人提交的申報 ☐

選擇適當的盒子:

支付申報費用（選中適用所有方框）:

初步代理資料 – 正在準備中

 

RXO，公司。

北社區House Road 11215號

北卡羅來納州夏洛特市28277

親愛的股東：

我們代表RXO, Inc.，一家特拉華州公司（「RXO」，「公司」，「我們」，「我們」或「我們」），邀請您參加公司股東的特別股東大會，該會議將於2024年12月5日上午7時30分東部時間（「特別會議」）召開。特別會議將僅以虛擬會議形式舉行。您將能夠參加特別會議，通過訪問現場網絡直播網站，以電子方式投票並在會議期間提交問題 www.virtualshareholdermeeting.com/RXO2024SM股東們可以在家或任何有互聯網連接的地方聆聽、投票並提交問題。要參加會議，您必須擁有代理卡上顯示的16位數字。隨後的會議通知和代理聲明將描述我們在會議上將考慮的業務。

2024年8月13日，公司完成了私人配售（「定向增發」）的發行和銷售，包括：（i）以每股20.21美元的價格發行的20,954,780股公司普通股，面值爲0.01美元/股（「普通股」），（ii）以每張權證20.20美元的價格向MFN合夥LP（「MFN」）和Orbis投資管理的某些帳戶（統稱爲「投資者」）發行的用於購買共計6,259,471股普通股的預融資權證（「權證」），以約550.0億美元的現金對價進行交易，扣除發行費用。公司利用定向增發所得的淨收入部分資助了其對Coyote物流的收購，該收購於2024年9月16日完成。

由於公司的普通股在紐約證券交易所（「紐交所」）上市，公司受紐交所的規則和法規約束。在特別會議上，您將被要求考慮並投票表決一項提案（「發行提案」），以便根據紐交所上市公司手冊第312.03節的規定，批准發行普通股用於行使部分權證購買3,700,718股普通股（「股東批准權證」）。如果公司獲得發行提案的股東批准，股東批准權證將可由持有人在任何時候自行選擇行使，而無需再次獲得公司股東的批准。行使其餘用於購買2,558,753股普通股的權證不受股東批准的限制，該等權證可由持有人根據進一步描述隨時自行選擇行使。

我們的董事會認爲發行提案符合公司及股東的最佳利益，因此建議您投票“ ”該發行提案。

此函附上的代理聲明向您提供了有關發行提案和公司股東特別會議的信息。我們鼓勵您仔細閱讀整個代理聲明。您還可以從我們在美國證券交易委員會提交的文件中獲取有關公司的更多信息。請查閱附帶代理聲明中的「您可以找到更多信息的地方」。

不論您持有多少股普通股，您的投票都很重要。無論您計劃是否出席特別會議，請按照您的代理卡上的說明儘快提交代理。您可以通過郵寄完成、簽署、日期並退回封裝的代理卡，或者您也可以通過電話或互聯網進行代理投票，具體操作請參閱代理卡上的進一步說明。我們鼓勵您通過互聯網或電話投票。如果您的普通股存放在經紀、交易商、商業銀行、信託公司或其他提名人的帳戶中，您應告知該經紀或其他提名人如何按照該經紀或其他提名人提供的投票指示表進行投票。

感謝您的合作和持續支持。

此致敬禮，

 

Brad Jacobs

董事會主席

[•], 2024

附帶的代理聲明日期爲2024年[•]，首次將於2024年[•]或之前寄給股東。

 

RXO，公司。

11215 北社區房屋路

北卡羅來納州夏洛特 28277

定於2024年12月5日舉行

致RXO公司股東：

特此通知，RXO公司股東大會（「股東大會」）將於2024年12月5日美國東部時間上午7:30通過網絡直播舉行 www.virtualshareholdermeeting.com/RXO2024SM:

董事會一致建議其股東投票 “ ” 提案中的每項。

2024年10月23日營業結束時，即「記載日期」，只有記錄股東才有資格收到特別股東大會以及特別股東大會任何休會或延期的通知、並進行投票。只能討論本特別股東大會通知中提到的事項，以及與這些事項有關的附帶事宜。請注意，如果在記載日期以「名義持股」（即通過經紀人、銀行或其他代表人）持有普通股，則被視爲這些股份的「實際所有人」。作爲這些股份的實際所有人，您有權指示您的經紀人、銀行或其他代表人如何投票。您將收到來自您的經紀人、銀行或其他代表人的投票指示，您必須按照這些指示投票以便使您的普通股股份被投票。

您需要在您的委託代理卡上包含的16位數字，才能加入特別股東大會。 www.virtualshareholdermeeting.com/RXO2024SM 並在特別股東大會期間投票您的股份或在特別股東大會期間提交問題。

即使您計劃參加特別股東大會，我們要求您按照代理卡上的說明儘快提交代理，以確保您的股份在不能出席會議時能在特別股東大會上得到代表。大多數股東可以選擇通過互聯網、電話或郵寄投票。請參考您的代理卡或附有這些代理材料的其他投票說明，了解您可用的投票方式。如果您通過互聯網或電話投票，您就不需要退回代理卡。如果您簽署、日期並退回代理卡而未指明希望如何投票，您的投票將被計爲對《發行提案》（如有必要和適當，還有《休會提案》）的投票。 如果您的股份由券商、經紀公司、商業銀行、信託公司或其他代理持有，您應按照由該券商或其他代理提供的投票指示表指示該券商或其他代理如何投票。

您的投票很重要。無論您是否計劃參加特別股東大會，您的股份被代表都很重要。我們請求您儘快投票。

董事會議案

 

 

Brad Jacobs

董事會主席

北卡羅來納州夏洛特

[•], 2024

References in this proxy statement to “RXO,” the “Company,” “we,” “us” or “our” refer to RXO, Inc. and include all of its consolidated subsidiaries, unless otherwise indicated or the context requires otherwise. References to the “Board” refer to our Board of Directors.

This proxy statement sets forth information relating to the solicitation of proxies by the Board in connection with a special meeting of stockholders (the “Special Meeting”) or any adjournment or postponement of the Special Meeting. This summary highlights information contained elsewhere in this proxy statement. This summary does not contain all the information that you should consider, and you should read the entire proxy statement carefully before voting.

This proxy statement and form of proxy are first being mailed on or about [•], 2024, to our stockholders of record as of the close of business on October 23, 2024 (the “Record Date”).

Admission: You are invited to attend the Special Meeting. The Special Meeting will be a virtual meeting of stockholders. You will be able to attend the Special Meeting at www.virtualshareholdermeeting.com/RXO2024SM. You will need to provide the control number on your proxy card to access the Special Meeting.

The Board is not aware of any matter that will be presented for a vote at the Special Meeting other than those shown below.

Only stockholders who held shares of our Common Stock as of the close of business on October 23, 2024, the “Record Date,” are entitled to receive notice of, and to vote at, the Special Meeting and at any adjournment or postponement of the Special Meeting.

If your shares are registered directly in your name with the Company’s transfer agent, Equiniti Trust Company LLC (formerly American Stock Transfer & Trust Company, LLC) (“Equiniti”), you are considered a stockholder of record with respect to those shares. You will receive one proxy card for all the shares you hold through book-entry form with Equiniti.

If your shares are held in a bank or brokerage account or through another nominee (that is, in “street name”), you are considered the “beneficial owner” of those shares. As the beneficial owner of those shares, you have the right to direct your broker, bank or other nominee how to vote your shares. You will receive instructions from your broker, bank or other nominee that you must follow in order to have your shares of Common Stock voted.

If you sign, date, and return your proxy card without indicating how you wish to vote, your vote will be counted as a vote “FOR” the Issuance Proposal and, if necessary and appropriate, the Adjournment Proposal.

For additional questions regarding the Issuance Proposal, assistance in submitting proxies or voting shares of our Common Stock, or to request additional copies of the proxy statement or the proxy card, please contact Investor Relations, RXO, Inc. by email at investors@rxo.com or send a written request to Jeffrey Firestone, Corporate Secretary, RXO, Inc., 11215 North Community House Road, Charlotte, North Carolina 28277.

The following questions and answers address briefly some questions you may have regarding the Special Meeting and the Proposals (as defined below). These questions and answers may not address all questions that may be important to you as a stockholder of the Company. Please refer to the more detailed information contained elsewhere in this proxy statement and the documents referred to or incorporated by reference in this proxy statement.

We are providing these proxy materials in connection with the solicitation by our Board of proxies to be voted at the Special Meeting in connection with the issuance of Common Stock upon exercise of the Stockholder Approval Warrants (as defined below).

On August 13, 2024, the Company completed the issuance and sale in a private placement (the “Private Placement”) of (i) an aggregate of 20,954,780 newly issued shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), at a purchase price of $20.21 per share and (ii) pre-funded warrants (the “Warrants”) to purchase an aggregate of 6,259,471 shares of Common Stock, at a purchase price of $20.20 per warrant, to MFN Partners, LP (“MFN”) and certain accounts managed by Orbis Investments (collectively, the “Investors”) in exchange for cash consideration in an aggregate amount of approximately $550.0 million, before deducting offering expenses. The Company used the net proceeds from the Private Placement to partially fund its acquisition of the technology-driven, asset light based truckload freight brokerage services business, as well as certain assets used to conduct haulage, dedicated transport and warehousing services in the United Kingdom, of United Parcel Service of America, Inc. (collectively, “Coyote Logistics”), which was completed on September 16, 2024 (the “Acquisition”).

Because the Company’s Common Stock is listed on New York Stock Exchange (the “NYSE”), the Company is subject to the NYSE’s rules and regulations. At the Special Meeting, you will be asked to consider and vote on a proposal (the “Issuance Proposal”) to approve, in accordance with Section 312.03 of the NYSE Listed Company Manual, the issuance of shares of the Common Stock to the Investors upon exercise of certain of the Warrants to purchase 3,700,718 shares of Common Stock (the “Stockholder Approval Warrants”). If the Company obtains stockholder approval of the Issuance Proposal, the Stockholder Approval Warrants will be exercisable, subject to certain limitations, at any time at the holder’s option without any further approval from the Company’s stockholders. The exercise of the remaining Warrants to purchase 2,558,753 shares of Common Stock is not subject to stockholder approval and such Warrants are exercisable, subject to certain limitations, at any time at the holder’s option as described further herein.

The holders of the Stockholder Approval Warrants will be unable to exercise the Stockholder Approval Warrants unless and until the Issuance Proposal is approved by our stockholders.

At the Special Meeting, in accordance with Section 312.03 of the NYSE Listed Company Manual, you will be asked to consider and vote to approve the Issuance Proposal.

Our Board believes that the Issuance Proposal is in the best interests of the Company and its stockholders and, therefore, recommends that you vote “FOR” the Issuance Proposal.

We expect that the business presented for a vote at the Special Meeting will be as follows:

The Special Meeting will be held on December 5, 2024 at 7:30 a.m., Eastern Time via live webcast at www.virtualshareholdermeeting.com/RXO2024SM. The Special Meeting will be held in a virtual meeting format only. You will not be able to attend the Special Meeting in person, but you will have the same opportunities to participate in the virtual meeting format as you would at an in-person meeting.

You are entitled to receive notice of and to virtually attend and vote at the Special Meeting, or any postponement or adjournment thereof, if, as of the close of business on October 23, 2024, the Record Date, you were a holder of record of our Common Stock.

As of the Record Date, there were [•] outstanding shares of our Common Stock, each of which is entitled to one vote on each matter to come before the Special Meeting. As of the Record Date, the Investors and their respective affiliates collectively owned [•] shares of our Common Stock, each of which is entitled to one vote on each matter to come before the Special Meeting.

If you were a stockholder of record as of the Record Date, to be admitted to the Special Meeting at www.virtualshareholdermeeting.com/RXO2024SM, and to vote your shares during the Special Meeting or submit questions during the Special Meeting, you must enter the control number found on your proxy card or voting instruction form you previously received. Stockholders of record may vote during the Special Meeting by following the instructions available on the meeting website during the Special Meeting.

The virtual meeting platform is fully supported across browsers (MS Edge, Firefox, Chrome, and Safari) and devices (desktops, laptops, tablets and cell phones) running the most up-to-date version of applicable software and plugins. Note: Internet Explorer is not a supported browser. You should ensure you have a strong Internet connection wherever you intend to participate in the Special Meeting. We encourage you to access the meeting prior to the start time. If you encounter any technical difficulties logging onto www.virtualshareholdermeeting.com/RXO2024SM or during the meeting, there will be a toll-free number and international number available on the website to assist you. Technical support will be available 15 minutes prior to the start time of the meeting and through the conclusion of the meeting.

A quorum is necessary to hold a valid meeting of stockholders. Pursuant to the Company’s bylaws, the presence, in person or by proxy, of the holders of a majority of the outstanding shares of Common Stock entitled to vote is necessary for each of the Proposals to be presented at the Special Meeting. If you vote—including by Internet, telephone or proxy card—your shares voted will be counted towards the quorum for the Special Meeting. Abstentions are counted as present for the purpose of determining a quorum; broker non-votes are not counted for the purpose of determining the presence of a quorum at the Special Meeting as the Proposals to be considered would not be considered routine by the NYSE.

You may vote “FOR” or “AGAINST” or you may “ABSTAIN” from voting on any Proposal to be voted on at the Special Meeting. Your shares will be voted as you specifically instruct. If you sign your proxy or voting instruction card without giving specific instructions, your shares will be voted in accordance with the recommendations of our Board and in the discretion of the proxy holders on any other matters that properly come before the Special Meeting. If you return your proxy card and “ABSTAIN” from voting, it will have the same effect as a vote against the Issuance Proposal and the Adjournment Proposal.

The Issuance Proposal requires the affirmative vote of a majority of the shares of Common Stock present in person or represented by proxy at the Special Meeting and entitled to vote. Under applicable NYSE rules, abstentions are counted as present for purposes of determining a quorum and are also counted as shares voted with respect to such proposal, and therefore, if you return your proxy card and “ABSTAIN” from voting, it will have the same effect as a vote against the Issuance Proposal. The Adjournment Proposal requires the affirmative vote of a majority of the shares of Common Stock present in person or represented by proxy and entitled to vote at the Special Meeting.

Upon exercise of the Stockholder Approval Warrants, the Company would issue approximately 3,700,718 shares of Common Stock, representing approximately [•]% of the total outstanding shares of Common Stock as of the Record Date, assuming the exercise price is paid in cash.

If the Issuance Proposal is not approved, the holders of the Stockholder Approval Warrants will not be able to exercise such Warrants and the Company must call a meeting every three months thereafter to seek stockholder approval until the earlier of the date stockholder approval is obtained or the Stockholder Approval Warrants are no longer outstanding.

Our Board unanimously recommends that our stockholders vote “FOR” the Issuance Proposal and “FOR” the Adjournment Proposal.

We urge you to read this proxy statement carefully and to consider how approving the Proposals affect you. Then simply mail your completed, dated and signed proxy card in the enclosed return envelope as soon as possible so that your shares can be voted at the Special Meeting of our stockholders. Holders of record may also vote by telephone or the Internet by following the instructions on the proxy card. If you vote by Internet or telephone, you do not need to return your proxy card.

If you fail to sign, date, and return your proxy card or fail to vote by telephone or Internet as provided on your proxy card, your shares will not be counted towards establishing a quorum for the Special Meeting, which requires holders representing a majority of the outstanding shares of our Common Stock to be present in person or by proxy. If you respond and do not indicate your voting preference, we will count your proxy as a vote in favor of the approval of each of the Proposals.

You should instruct your broker or other nominee on how to vote your shares using the instructions provided by such broker or other nominee. Absent specific voting instructions, brokers or other nominees who hold shares of Common Stock in “street name” for customers are prevented by the NYSE Rules from exercising voting discretion in respect of non-routine or contested matters. The Company expects that when the NYSE evaluates the Proposals to be voted on at the Special Meeting to determine whether each Proposal is a routine or non-routine matter, the Proposals would not be considered routine. Shares not voted by a broker or other nominee because such broker or other nominee does not have instructions or cannot exercise discretionary voting power with respect to one or more Proposals are referred to as “broker non-votes”. Such broker non-votes may not be counted for the purpose of determining the presence of a quorum at the Special Meeting in the absence of a routine proposal. Therefore, it is important that you instruct your broker or other nominee on how to vote your shares of Common Stock held in “street name” in accordance with the voting instructions provided by such broker or other nominee.

If you are a registered stockholder (i.e., you hold your shares in your own name through our transfer agent, Equiniti Trust Company LLC (formerly American Stock Transfer & Trust Company, LLC), and not through a broker, bank, or other nominee that holds shares for your account in “street name”), you may vote by proxy via the Internet, by telephone, or by mail by following the instructions provided on the proxy card. Proxies submitted by telephone or through the Internet must be received by 11:59 p.m., Eastern Time, on December 4, 2024. Please see the proxy card provided to you for instructions on how to submit your proxy by telephone or the Internet. Stockholders of record who attend the Special Meeting may vote by logging into the virtual meeting at www.virtualshareholdermeeting.com/RXO2024SM. We encourage you to log on 15 minutes prior to the start of the Special Meeting.

If you are a beneficial owner of shares (i.e., your shares are held in the name of a brokerage firm, bank or a trustee), you may vote by proxy by following the instructions provided in the vote instruction form or other materials provided to you by the brokerage firm, bank, or other nominee that holds your shares.

Yes. Whether you attend the Special Meeting or not, any proxy given pursuant to this solicitation may be revoked by the person giving it at any time before it is voted. If you are a holder of record, your proxy may be revoked in writing to the Company’s Corporate Secretary, at or before taking of the vote at the Special Meeting. A written notice of revocation or a duly executed proxy, in either case later dated than the prior proxy relating to the same shares, will be treated as the final vote.

Holders of record may also revoke their proxies by attending the Special Meeting and voting during the live webcast at www.virtualshareholdermeeting.com/RXO2024SM, although attendance at the Special Meeting will not itself revoke a proxy. Any written notice of revocation or subsequent proxy should be sent so as to be delivered to Jeffrey Firestone, Corporate Secretary, RXO, Inc., 11215 North Community House Road, Charlotte, North Carolina 28277. Any written notice of revocation must be received at such address by 11:59 p.m., Eastern Time, on December 4, 2024.

If you hold your shares in “street name” through a broker, dealer, commercial bank, trust company, or other nominee, you should follow the instructions of such broker or other nominee regarding revocation of proxies.

We intend to announce preliminary voting results at the Special Meeting and will publish final results on a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission (“SEC”) within four business days after the Special Meeting. The Current Report on Form 8-K will also be available on our website at investors.rxo.com.

Yes. A list of these stockholders will be open for examination by any stockholder for any purpose germane to the Special Meeting for a period of 10 days prior to the Special Meeting and electronically during the Special Meeting at www.virtualshareholdermeeting.com/RXO2024SM.

The Company is paying the costs of the solicitation of proxies. The Company may also reimburse brokerage firms, banks, broker-dealers or other similar organizations for the cost of forwarding proxy materials to beneficial owners. In addition, certain of the Company’s directors, officers and regular employees, without additional compensation, may solicit proxies on the Company’s behalf in person, by telephone, by fax or by electronic mail. See “Proxy Solicitation and Costs” in this proxy statement for further information.

In cases where multiple company stockholders share the same address, and the shares are held through a bank, broker, or other holder of record in a street-name account, only one copy of our proxy materials will be delivered to that address unless a stockholder at that address requests otherwise. This practice, known as “householding,” is intended to reduce our printing and postage costs. However, any street-name stockholders residing at the same address who wish to receive a separate copy of our proxy materials may request a copy by contacting their bank, broker or other holder of record, or by sending a written request to Jeffrey Firestone, Corporate Secretary, RXO, Inc., 11215 North Community House Road, Charlotte, North Carolina 28277, or by contacting Investor Relations by email at investors@rxo.com. The voting instruction form sent to a street-name stockholder should provide information on how to request a separate copy of future materials for each company stockholder at that address, if that is your preference. Similarly, if you currently receive separate copies of our proxy materials but wish to participate in householding, please contact us through the method described above.

Yes, this proxy statement, the accompanying notice of Special Meeting and the proxy card are available at www.proxyvote.com or investors.rxo.com.

Although it is not expected, the Special Meeting may be adjourned or postponed for the purpose of soliciting additional proxies. Any adjournment or postponement may be made without notice, other than by an announcement made at the Special Meeting, by the Chairman of the Board, the Chief Executive Officer or such other person as may be designated chairman of the Special Meeting, whether or not a quorum exists. Any signed proxies received by the Company will be voted in favor of an adjournment or postponement in these circumstances. Any adjournment or postponement of the Special Meeting for the purpose of soliciting additional proxies will allow Company stockholders who have already sent in their proxies to revoke them at any time prior to their use.

No. Our stockholders are not entitled to dissenters’ rights or appraisal rights under the General Corporation Law of the State of Delaware (the “DGCL”) for the matters being submitted to stockholders at the Special Meeting, and the Company will not independently provide stockholders with any such right.

If you have more questions about the Proposals or voting, you should contact Jeffrey Firestone, Corporate Secretary, RXO, Inc., 11215 North Community House Road, Charlotte, North Carolina 28277, or Investor Relations at investors@rxo.com.

On August 13, 2024, the Company completed the Private Placement of (i) an aggregate of 20,954,780 newly issued shares of Common Stock, at a purchase price of $20.21 per share (the “Shares”) and (ii) Warrants to purchase an aggregate of 6,259,471 shares of Common Stock (the “Warrant Shares”), at a purchase price of $20.20 per warrant, to the Investors in exchange for cash consideration in an aggregate amount of approximately $550.0 million, before deducting offering expenses. The Company used the net proceeds from the Private Placement to partially fund the Acquisition.

The Warrants are exercisable at any time, subject to certain conditions described below, at an exercise price of $0.01 per share (as adjusted from time to time pursuant to the terms of the Warrants). The exercise of (i) Warrants to purchase 3,700,718 shares of Common Stock, which we also refer to as the Stockholder Approval Warrants, is subject to the receipt of the stockholder approval described in this proxy statement (the “Stockholder Approval Condition”), and (ii) Warrants to purchase 4,577,327 shares of Common Stock (which includes Stockholder Approval Warrants to purchase 2,018,574 shares of Common Stock) is subject to a condition that the holder of the Warrants, following the exercise of the Warrants, would not beneficially own, together with any attribution parties, in excess of 19.9% of the Company (the “Beneficial Ownership Limitation”). Holders of the Warrants are not entitled to any rights of a stockholder of the Company, including the right to vote or consent with respect to any matter, prior to exercising their Warrants; however, holders of Warrants will be entitled to receive pro rata distributions on Common Stock, subject, for applicable Warrants, to the Stockholder Approval Condition and Beneficial Ownership Limitation.

Because the Company’s Common Stock is listed on the NYSE, the Company is subject to the NYSE’s rules and regulations. Section 312.03 of the NYSE Listed Company Manual (“NYSE Rule 312.03”) requires us, subject to certain exceptions, to obtain stockholder approval prior to the issuance of shares of our Common Stock if, among other things, (i) the Common Stock issued will have voting power equal to or in excess of 20% of the voting power outstanding before the issuance of such stock or (ii) the number of shares of Common Stock will be upon issuance, equal to or in excess of 20% of the number of shares of Common Stock outstanding before the issuance.

Due to NYSE Rule 312.03, the holders of the Stockholder Approval Warrants are unable to exercise such Warrants unless and until stockholder approval is obtained. If the Company obtains stockholder approval, the Stockholder Approval Warrants will be exercisable, subject to certain limitations, at any time at the holder’s option without any further approval from the Company’s stockholders. The exercise of the remaining Warrants to purchase 2,558,753 shares of Common Stock is not subject to stockholder approval and such Warrants are exercisable, subject to certain limitations, at any time at the holder’s option as described above.

At the Special Meeting, in accordance with NYSE Rule 312.03, you will be asked to consider and vote to approve the Issuance Proposal. Immediately prior to the issuance of the Warrants and shares of Common Stock in connection with the Private Placement, the Investors and their respective affiliates collectively beneficially owned approximately 29% of the Company’s outstanding Common Stock.

The Issuance Proposal requires the affirmative vote of a majority of the shares of common stock present in person or represented by proxy at the Special Meeting and entitled to vote. Under applicable NYSE Rules, abstentions are counted as present for purposes of determining a quorum and are also counted as shares voted with respect to such proposal, and therefore, if you return your proxy card and “ABSTAIN” from voting, it will have the same effect as a vote against the Issuance Proposal.

A vote in favor of the Issuance Proposal is a vote in favor of approving, for purposes of the rules of the NYSE, the issuance of the shares underlying the Stockholder Approval Warrants.

Approval of the Issuance Proposal will not affect the rights or privileges of current holders of outstanding shares of Common Stock but such issuance will have a dilutive effect on the existing stockholders, including the voting power and economic rights of the existing stockholders. If the Issuance Proposal is approved, the Investors will have the ability to acquire up to an additional 3,700,718 shares of Common Stock by exercising the Stockholder Approval Warrants, which represent approximately [•]% of the total outstanding shares of Common Stock as of the Record Date, assuming the exercise price is paid in cash. If the Issuance Proposal is approved and assuming all of the Warrants issued in the Private Placement are exercised solely for cash, the Investors would have held, as of the Record Date, [•]% of the voting power of the Company.

Pursuant to the Purchase Agreements (as defined below), if the Company does not obtain approval of the Issuance Proposal at the first meeting of stockholders, the Company must call a meeting every three months thereafter to seek approval of the Issuance Proposal until the earlier of the date approval is obtained or the Stockholder Approval Warrants are no longer outstanding.

Our directors and executive officers have no substantial interests, directly or indirectly, in the matters set forth in this Issuance Proposal except to the extent of their ownership of shares of our Common Stock.

The Company has the following arrangements with the Investors:

The Company entered into purchase agreements, each dated as of August 12, 2024, with the Investors (collectively, the “Purchase Agreements”), pursuant to which the Company consummated the Private Placement. The Purchase Agreements contain customary representations, warranties and agreements by the Company, indemnification obligations of the Company and the Investors, including for liabilities under the Securities Act of 1933, as amended, and other obligations of the parties.

Pursuant to the terms of the Purchase Agreements, we agreed to hold a special meeting of stockholders to obtain stockholder approval of the issuance of the shares underlying the Stockholder Approval Warrants pursuant to the applicable rules and regulations of the NYSE (the “Stockholder Approval”), at the earliest practicable date, but in no event later than December 31, 2024. If we do not obtain Stockholder Approval at the first meeting, we have agreed to call a special meeting every three months thereafter to seek the Stockholder Approval until the earlier of the date the Stockholder Approval is obtained or the Stockholder Approval Warrants are no longer outstanding.

Under the terms of the Purchase Agreements, the Investors agreed to a lock-up with respect to the securities purchased pursuant to the Purchase Agreements for a period of 120 days. In addition, the Purchase Agreements provide certain registration rights, pursuant to which we have agreed to register the resale of the Shares and the Warrant Shares. We are required to use commercially reasonable efforts to file a registration statement with the SEC covering the resale by the Investors of their Shares and the Warrant Shares within 90 days following the closing of the Private Placement.

OUR BOARD UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THE APPROVAL OF PROPOSAL 1.

The Company’s stockholders are being asked to consider and vote on a proposal to adjourn or postpone the Special Meeting, if necessary, to solicit additional proxies.

If the Company stockholders approve the Adjournment Proposal, the Company could adjourn the Special Meeting and any adjourned session of the Special Meeting and use the additional time to solicit additional proxies, including the solicitation of proxies from stockholders that have previously returned properly executed proxies voting against approval of the Issuance Proposal. Additionally, the Company may seek to adjourn the Special Meeting if a quorum is not present at the Special Meeting.

The Adjournment Proposal requires the affirmative vote of a majority of the shares of common stock present in person or represented by proxy at the Special Meeting and entitled to vote. Under applicable NYSE Rules, abstentions are counted as present for purposes of determining a quorum and are also counted as shares voted with respect to such proposal, and therefore, if you return your proxy card and “ABSTAIN” from voting, it will have the same effect as a vote against the Adjournment Proposal.

OUR BOARD UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THE APPROVAL OF PROPOSAL 2.

The following table sets forth information concerning the beneficial ownership of our voting securities as of September 30, 2024 by: (i) each person who is known by us, based solely on a review of public filings, to be the beneficial owner of more than 5% of any class of our outstanding voting securities, (ii) each director, (iii) each named executive officer (“NEO”), and (iv) all executive officers and directors as a group.

Under applicable SEC rules, a person is deemed to be the “beneficial owner” of a voting security if such person has (or shares) either investment power or voting power over such security or has (or shares) the right to acquire such security within 60 days by any of a number of means, including upon the exercise of options or warrants or the conversion of convertible securities. A beneficial owner’s percentage ownership is determined by assuming that options, warrants and convertible securities that are held solely by the beneficial owner, and which are exercisable or convertible within 60 days, have been exercised or converted. Unless otherwise indicated, we believe that all persons named in the table below have sole voting and investment power with respect to all voting securities shown as being owned by them. Unless otherwise indicated, the address of each beneficial owner in the table below is care of RXO, Inc., 11215 North Community House Road, Charlotte, North Carolina 28277.

No business other than that set forth in the attached notice of Special Meeting is expected to come before the Special Meeting. However, should any other matters requiring a vote of stockholders arise, the persons named in the accompanying proxy will vote thereon according to their best judgment in the interest of the Company.

It is expected that the solicitation of proxies will be primarily by mail. Proxies may also be solicited personally by regular employees of the Company, by telephone or by other means of communication at nominal cost. The Company will bear the cost of such solicitation. It will reimburse banks, brokers and trustees, or their nominees, for reasonable expenses incurred by them in forwarding proxy material to beneficial owners of stock in accordance with the NYSE schedule of charges.

The Company will bear the entire cost of this solicitation of proxies, including the preparation, assembly, printing and mailing of this proxy statement, the proxy card and any additional solicitation material that the Company may provide to stockholders. Copies of solicitation material will be provided to brokerage firms, fiduciaries and custodians holding shares in their names that are beneficially owned by others so that they may forward the solicitation material to such beneficial owners. Further, the original solicitation of proxies by mail may be supplemented by solicitation by telephone and other means by directors, executive officers and employees of the Company. No additional compensation will be paid to these individuals for any such services. The Company will also post its proxy materials to its website at www.rxo.com.

If you would like to include a proposal for stockholder consideration in the proxy statement for our next annual meeting of stockholders or otherwise bring business before our annual meeting of stockholders, you must send notice to Company at Jeffrey Firestone, Corporate Secretary, RXO, Inc., 11215 North Community House Road, Charlotte, North Carolina 28277, by registered, certified, or express mail and provide the required information and follow the other procedural requirements described below.

Stockholders who wish to present a proposal in accordance with the SEC Rule 14a-8 for inclusion in our proxy materials to be distributed in connection with our next annual meeting of stockholders must submit their proposals in accordance with that rule so that they are received by the Secretary at the address set forth above no later than the close of business on December 10, 2024. If the date of our next annual meeting is either before April 20, 2024 or after July 19, 2025, then the deadline to timely receive such material shall be a reasonable time before we begin to print and send our proxy materials. Failure to deliver a proposal in accordance with this procedure may result in it not being deemed timely received. As the rules of the SEC make clear, simply submitting a timely proposal does not guarantee that it will be included in our proxy materials.

If a stockholder wishes to present a proposal or nominate a director at our next annual meeting other than a matter brought pursuant to SEC Rule 14a-8 for inclusion in our proxy statement, the stockholder must give our Corporate Secretary written notice of the stockholder’s intent to do so and provide the information required by the provision of our bylaws dealing with stockholder proposals and nominations. The notice of such a proposal or director nomination must be delivered to (or mailed to and received at) the address set forth above no later than December 10, 2024 and no earlier than November 10, 2024; provided, however, that if we elect to hold the annual meeting either before April 20, 2024 or after July 19, 2025, notice will be timely if delivered not earlier than 120 days prior to the annual meeting or later than the later of (a) 90 days prior to the annual meeting or (b) the tenth day following the day on which public announcement of the annual meeting date is made. Your notice must set forth the information required by our bylaws with respect to each proposal that the eligible stockholder or stockholders intend to present at our next annual meeting and must otherwise be in compliance with our bylaws. If you would like a copy of these procedures, please contact our Corporate Secretary for a copy of our bylaws.

We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC website at www.sec.gov. You also may obtain free copies of the documents we file with the SEC, including this proxy statement, by going to our corporate website at investors.rxo.com. The information provided on our website, other than copies of the documents listed below that have been filed with the SEC, is not part of this proxy statement, and therefore is not incorporated herein by reference.

The SEC allows us to “incorporate by reference” the information we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this proxy statement. Information that we file later with the SEC will automatically update and supersede information in this proxy statement. In all cases, you should rely on the later information over different information included in this proxy statement. The following documents have been filed by us with the SEC and are incorporated by reference into this proxy statement:

All reports and other documents that we subsequently file with the SEC (other than any portion of such filings that are furnished under applicable SEC rules rather than filed) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this proxy statement and before the date of the Special Meeting will be deemed to be incorporated by reference into this proxy statement and to be part of this proxy statement from the date of filing of such reports and documents.

You should not assume that the information in this proxy statement or any document incorporated by reference is accurate as of any date other than the date of the applicable document. Any statement contained in a document incorporated or deemed to be incorporated by reference into this proxy statement will be deemed to be modified or superseded for purposes of this proxy statement to the extent that a statement contained in or omitted from this proxy statement or any other subsequently filed document that is deemed to be incorporated by reference into this proxy statement modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this proxy statement.

You may request a copy of any or all documents referred to above that have been or may be incorporated by reference into this proxy statement (excluding certain exhibits to the documents) at no cost, by writing or calling us at the following address or telephone number:

RXO, Inc.

Attention: Chief Legal Officer

11215 North Community House Road

Charlotte, North Carolina 28277

(980) 308-6058

In cases where multiple company stockholders share the same address, and the shares are held through a bank, broker, or other holder of record in a street-name account, only one copy of our proxy materials will be delivered to that address unless a stockholder at that address requests otherwise. This practice, known as “householding,” is intended to reduce our printing and postage costs. However, any street-name stockholders residing at the same address who wish to receive a separate copy of our proxy materials may request a copy by contacting their bank, broker or other holder of record, or by sending a written request to Jeffrey Firestone, Corporate Secretary, RXO, Inc., 11215 North Community House Road, Charlotte, North Carolina 28277, or by contacting Investor Relations by email at investors@rxo.com. The voting instruction form sent to a street-name stockholder should provide information on how to request a separate copy of future materials for each company stockholder at that address, if that is your preference. Similarly, if you currently receive separate copies of our proxy materials but wish to participate in householding, please contact us through the method described above.

Copies of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (not including exhibits and documents incorporated by reference unless such exhibits are specifically incorporated by reference into the proxy statement) or this proxy statement are available without charge to stockholders upon written request to the Company at Investor Relations, RXO, Inc., 11215 North Community House Road, Charlotte, North Carolina 28277 or by email at investors@rxo.com.

Although we include references to our website, www.rxo.com, and certain additional third-party websites, throughout this proxy statement, information that is included on our website is not incorporated by reference into, and is not a part of, this proxy statement. Our website address is included as an inactive textual reference only.

We use our website as one means of disclosing material non-public information and for complying with our disclosure obligations under the SEC’s Regulation FD. Such disclosures typically will be included within the Investor Relations section of our website. Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts.